Full Press Release Details
Kadima Neuropsychiatry Institute, featured in the documentary (begins around the 24 minute mark of the documentary), has been identified as a planned HOPE Flagship Clinic acquisition.
Watch the Peacock Trailer:
NRXP Negative Sentiment
Matthew Perry: A Hollywood Tragedy is a new documentary on how the Friends star died in 2023
Key Takeaway: The article discusses a new documentary about Matthew Perry, focusing on his tragic death in 2023. It mentions the Kadima Neuropsychiatry Institute, which is featured in the documentary and is linked to a planned acquisition. The documentary aims to shed light on the circumstances surrounding Perry's death and its impact.
Price reaction · baseline $2.22 (2025-03-06T16:48:00.000Z) · hit during market hours · clean, no other NRXP news in the window
day 0 close · peak
-2.7%
Market Sentiment Analysis
CONCERNS & RISKS
- The documentary discusses the tragic death of Matthew Perry.
- It highlights the emotional impact of his passing on fans and the industry.
- The focus on his death may evoke sadness and concern about mental health.
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial adviceBest trade, last catalyst
+167%
120-day peak, hindsight
Typical move
4.3%
average across 2 past catalysts
Cash runway
~12 mo
Low dilution risk
Lead asset
NRX-101
Phase 2 · Bipolar Depression
Frequently Asked Questions
What is the focus of the new documentary on Matthew Perry?
The documentary focuses on the tragic circumstances surrounding Matthew Perry's death.
Which institute is featured in the documentary?
The Kadima Neuropsychiatry Institute is featured in the documentary.
What is the planned acquisition mentioned in the article?
The Kadima Neuropsychiatry Institute is identified as a planned HOPE Flagship Clinic acquisition.